Integration of estrogen and progesterone receptors with pathological and molecular prognostic factors in breast cancer patients

Carter, 1989, Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases, Cancer, 63, 181, 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H Rosen, 1989, A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma, J. Clin. Oncol., 7, 355, 10.1200/JCO.1989.7.3.355 Rosen, 1989, Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18years, J. Clin. Oncol., 7, 1239, 10.1200/JCO.1989.7.9.1239 Gardner, 1993, Are positive axillary nodes in breast cancer markers for incurable disease?, Ann. Surg., 218, 270, 10.1097/00000658-199309000-00006 Ciocca, 1992, Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers, J. Natl Cancer Inst., 84, 1279, 10.1093/jnci/84.16.1279 Wolf, 1992, Detection of proliferating cell nuclear antigen in diagnostic histopathology, J. Histochem. Cytochem., 40, 1269, 10.1177/40.9.1354677 Ciocca, 1993, Heat, shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications, J. Natl Cancer Inst., 85, 570, 10.1093/jnci/85.7.570 Porter-Jordan, 1994, Overview of the biologic markers of breast cancer, Hematol./Oncol. Clinics N. Am., 8, 73, 10.1016/S0889-8588(18)30188-6 Ciocca, 1994, Estrogen receptors in the human female genital tract in normal and pathological conditions: review, Biocell, 18, 1 Elledge, 1996, Assessing p53 status in breast cancer prognosis: where should you put the thermometer if you think your p53 is sick?, J. Natl Cancer Inst., 88, 141, 10.1093/jnci/88.3-4.141 Bertin, 1997, Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: correlation with prognostic factors, tumor angiogenesis, and fibroblastic desmoplasia, Cancer Res., 57, 396 van Diest, 1997, Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value, Am. J. Pathol., 150, 705 Bloom, 1957, Histological grading and prognosis in breast cancer: study of 1,409 cases of which 359 have been followed for 15years, Br. J. Cancer, 11, 359, 10.1038/bjc.1957.43 Fanelli, 1996, Estrogen receptors, progesterone receptors, and cell proliferation in human breast cancer, Breast Cancer Res. Treat., 37, 217, 10.1007/BF01806503 Shi, 1991, Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections, J. Histochem. Cytochem., 33, 741, 10.1177/39.6.1709656 Shi, 1995, Antigen retrieval immunostaining under the influence of pH using monoclonal antibodies, J. Histochem. Cytochem., 43, 193, 10.1177/43.2.7822775 Al Saati, 1993, Production of monoclonal antibodies to human estrogen-receptor (ER) using recombinant ER (RER), Int. J. Cancer, 55, 651, 10.1002/ijc.2910550423 Perrot-Applanat, 1987, Immunocytochemical study with monoclonal antibodies to progesterone receptor in human breast tumors, Cancer Res., 47, 2652 Hall, 1990, Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms, J. Pathol., 162, 285, 10.1002/path.1711620403 Molina, 1992, Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and Western blot techniques, Anticancer Res., 12, 1965 Vojtesek, 1992, An immunochemical analysis of human nuclear phosphoprotein p53: new monoclonal antibody and epitope mapping using recombinant p53, J. Immunol. Meth., 151, 237, 10.1016/0022-1759(92)90122-A Rao, 1994, MDR1 gene-specific monoclonal antibody C494 cross-reacts with pyruvate carboxylase, Cancer Res., 54, 1536 Toth, 1994, New immunohistochemical “sandwich” staining method for mdr1 P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues, Am. J. Pathol., 144, 227 Elledge, 1993, Estrogen receptors, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients, Cancer, 71, 2499, 10.1002/1097-0142(19930415)71:8<2499::AID-CNCR2820710812>3.0.CO;2-S Vargas Roig, 1993, Effects of short-term tamoxifen administration in patients with invasive cervical carcinoma, Anticancer Res., 13, 2457 Allred, 1998, Prognostic and predictive factors in breast cancer by immunohistochemical analysis, Mod. Pathol., 11, 155 Kelman, 1997, PCNA: structure, functions and interactions, Oncogene, 14, 629, 10.1038/sj.onc.1200886 Ravdin, 1996, A computer program to assist in making breast cancer adjuvant therapy decisions, Seminars Oncol., 23, 43 Possinger, K., Wischnewsky, M., Schonborn, I. and Lichtenegger, W. What can we do with prognostic and predictive factors in breast cancer? In 21th ESMO Congress, Educational Programme, Vienna, Austria, 1996, pp. 1–5 Sauerbrei, 1997, Validation of existing and development of new prognostic classification schemes in node negative breast cancer, Breast Cancer Res. Treat., 42, 149, 10.1023/A:1005733404976 McGuire, 1986, Role of steroid hormone receptors as prognostic factors in primary breast cancer, NCI Monogr., 1, 19 Tandon, 1989, HER-2/neu oncogene protein and prognosis in breast cancer, J. Clin. Oncol., 7, 1120, 10.1200/JCO.1989.7.8.1120 Verrelle, 1991, Clinical relevance of immunohistochemical detection of multidrug resistance, P-glycoprotein in breast carcinoma, J. Natl Cancer Inst., 83, 111, 10.1093/jnci/83.2.111 Elledge, 1993, Prognostic significance of p53 gene alterations in node-negative breast cancer, Breast Cancer Res. Treat., 26, 225, 10.1007/BF00665800 Trock, 1996, Multidrug resistance in breast cancer: a meta-analysis of the occurrence and prognostic significance of MDR1/gp170 expression, Proc. AACR, 37, 1344 Lowe, 1993, p53-dependent apoptosis modulates the cytotoxicity of anticancer agents, Cell, 74, 957, 10.1016/0092-8674(93)90719-7 Muss, 1994, c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer, N. Engl. J. Med., 330, 1260, 10.1056/NEJM199405053301802 Rusch, 1995, Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer, Cancer Res., 55, 5038 Bitran, 1996, Clin. Cancer Res., 2, 1509 Vargas-Roig, L. M., Gago, F. E., Tello, O., Martı́n de Civetta, M. T. and Ciocca, D. R., c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy. Int. J. Cancer, in press